Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Regulatory News:


Aptorum Group Limited , a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today... | April 28, 2023

Related Keywords

Jingdong ,Guangdong ,China ,Singapore ,United States ,Canada ,Darren Lui ,Aptorum Group Or We ,Daptorum Group ,Aptorum Group Cayman ,Singapore Agency For Science ,Nasdaq ,Holding Group ,Aptorum Group Form ,Aptorum Group Limited Nasdaq ,Drug Administration ,Yu Group ,Regulatory News ,Group Limited ,Euronext Paris ,Chief Executive Officer ,Executive Director ,Methicillin Resistant Staphylococcus ,Pipeline Update ,Methicillin Resistant Staphylococcus Aureus ,Acute Bacterial Skin ,Skin Structure Infections ,Ordinary Shares ,Ordinary Share ,Aptorum Group Cayman Limited ,Classb Ordinary Shares ,Term Sheet ,Aptorum Group Limited ,Securities Litigation Reform Act ,French Autorit ,Des March ,Regulations Delegated ,Years Ended December ,Aptorum Group Limited Stock Exchange ,News ,Information ,Press Release ,Egulatory ,Group ,Imited ,Linical ,Stage ,Iopharmaceutical ,Company ,Edicated ,O ,Meeting ,Unmet ,Medical ,Needs ,N ,Autoimmune ,Diseases ,End ,Nfectious Apm Kyg6096m1226 ,